HER2-Positive Breast Cancer Medical Services in China

HER2-positive breast cancer is an aggressive subtype characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein, detected via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Accounting for approximately 15–20% of invasive breast cancers, it exhibits rapid proliferation, higher recurrence risk, and poorer prognosis without targeted intervention. However, the advent of HER2-directed therapies—including monoclonal antibodies (tr pertuzumab), antibody-drug conjugates (fam-trastuzumab deruxtecan-nxki), and tyrosine kinase inhibitors (lapatinib, tucatinib)—has transformed outcomes, significantly improving progression-free and overall survival, especially when integrated into neoadjuvant, adjuvant, or metastatic treatment regimens.

China offers compelling advantages for international patients seeking HER2-positive breast cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—host nationally certified HER2 testing laboratories and multidisciplinary tumor boards with extensive experience in complex cases. Advanced imaging (3.0T MRI, digital PET-CT), robotic-assisted surgery, and early access to globally approved biologics—including biosimilar trastuzumab with equivalent efficacy and safety profiles—enhance therapeutic precision. Clinical outcomes align with international benchmarks: five-year disease-free survival exceeds 85% in early-stage patients receiving guideline-concordant dual HER2 blockade. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality—drugs, diagnostics, and hospital stays remain rigorously regulated by China’s National Medical Products Administration (NMPA).

As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital accreditation, coordinating appointments with certified oncologists, providing itemized, transparent pricing in advance, arranging visa support, interpreters, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.

Medical Travel to China Guide: HER2-Positive Breast Cancer

Most nationalities require a Chinese visa for medical treatment; we assist with the Medical Visa (Q2 or S2) application, providing invitation letters from partner hospitals and supporting documentation. Entry requires a valid passport, negative PCR test within 48 hours pre-departure (requirements subject to change—our team confirms current rules).

Medical insurance is not accepted by most Chinese hospitals for international patients; however, our agency offers transparent, all-inclusive pricing—covering diagnostics, targeted therapy (e.g., trastuzumab, pertuzumab), surgery, and follow-up consultations—with no hidden fees. We coordinate direct payments via bank transfer or credit card, and provide itemized cost breakdowns before treatment begins.

We arrange comfortable, hospital-proximate accommodations (including apartment-style options for companions) and support visa applications for one caregiver.

Post-treatment, our dedicated care coordinators manage remote follow-up: scheduling virtual oncology reviews, sharing pathology reports in English, coordinating prescription refills, and liaising with your home-country doctors for seamless continuity of care. All services are included in our patient journey package—no extra charges, no surprises.